cyclover structure

Cyclover is coined to refer to a lipophilic anchor of a lipophilic reagent containing a triazine core having specified aliphatic groups. In terms of its composition for etymology, Cyclover is composed of initial two letters inherited from cyanuric core (triazine) having a molecular structure resembling a clover. Clover is a plant having green leaves divided into commonly three leaflets, occasionally four leaflets, possibly many more leaflets, each leaflet herein symbolizing a long alkyl chain in the lipophilic anchor. More meaningfully in its function, the lipophilic reagent containing the lipophilic anchor has a property of reproducibly changing from a soluble state to a solid state according to changes in the solution composition. In a multi-step synthesis, each cycle of a reaction involves simply mixing with reactants in solution for complete reaction followed by precipitating with change of solution composition followed by filtering to obtain the desired product. The cycle can be technically performed over and over again. Cyclover is thus created from hybridization of cycle and over. The technique of the multi-cycle process is termed as Cyclophase synthesis. Cyclover is a lipophilic anchor wherein Cyclover reagent or Cyclover derivative are soluble in one system of solvent(s) and become insoluble after changes of solvent system, thus representing a revolution in organic synthesis technology wherein pure product at each step as a solid can be rapidly obtained with ease and certainty.

Structure: *

CA Index Name:

N2,N2,N4,N4-tetraoctadecyl-6-(1-piperazinyl)-1,3,5-triazine-2,4-diamine

CAS Registry Number (CAS RN): 3018086-90-0

Significance: ​

1. Silica gel chromatographic purification is obsolete for general organic synthesis.

2. Green chemistry for minimizing the use of resources and enhancing the productivity, removing the bottleneck of industrial scalability.

3. Efficient and identical process for drug synthesis from discovery to development, paving a smooth and speedy path from clinical trial to drug approval.

​

*Yongfu Li: Composition of a lipophilic agent for solution phase synthesis of biomolecules

US2023/0373936A1 and WO2023/244274A2.